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Abstract
Background: BAFF and APRIL share two receptors – TACI and BCMA – and BAFF binds to a
third receptor, BAFF-R. Increased expression of BAFF and APRIL is noted in hematological
malignancies. BAFF and APRIL are essential for the survival of normal and malignant B lymphocytes,
and altered expression of BAFF or APRIL or of their receptors (BCMA, TACI, or BAFF-R) have
been reported in various B-cell malignancies including B-cell non-Hodgkin's lymphoma, chronic
lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenstrom's
macroglobulinemia.
Methods: We compared the expression of BAFF, APRIL, TACI and BAFF-R gene expression in 40
human tumor types – brain, epithelial, lymphoid, germ cells – to that of their normal tissue
counterparts using publicly available gene expression data, including the Oncomine Cancer
Microarray database.
Results: We found significant overexpression of TACI in multiple myeloma and thyroid carcinoma
and an association between TACI expression and prognosis in lymphoma. Furthermore, BAFF and
APRIL are overexpressed in many cancers and we show that APRIL expression is associated with
tumor progression. We also found overexpression of at least one proteoglycan with heparan
sulfate chains (HS), which are coreceptors for APRIL and TACI, in tumors where APRIL is either
overexpressed or is a prognostic factor. APRIL could induce survival or proliferation directly
through HS proteoglycans.
Conclusion: Taken together, these data suggest that APRIL is a potential prognostic factor for a
large array of malignancies.
Background
APRIL and BAFF are two members of the TNF family. BAFF
is a type II transmembrane protein that can be secreted
after proteolytical cleavage from the cell membrane[1,2].
APRIL is processed intracellularly within the Golgi appa-
ratus by a furin pro-protein convertase prior to secretion
of the biologically active form[3]. APRIL can also be
expressed as a cell surface fusion protein with TWEAK
called TWE-PRIL[4,5]. Both ligands bind to TACI (trans-
membrane activator and CAML interactor) and BCMA (B-
cell maturation antigen), two members of the TNFR fam-
ily. BAFF binds additionally to BAFF receptor (BAFF-R).
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BAFF is involved in the survival of normal and malignant
B cells and normal plasmablasts [6-8]. APRIL is highly
expressed in several tumor tissues, stimulates the growth
of tumor cells[9] and promotes survival of normal plas-
mablasts and plasma cells[10,11].
Evidence has been presented that BAFF/APRIL contribute
to malignancies of B cells and plasma cells: non-Hodg-
kin's lymphoma [12-16], Hodgkin lymphoma[17],
chronic lymphocytic leukemia[18,19], multiple myeloma
[20-24] and Waldenstrom's macroglobulinemia[25].
Recombinant APRIL binds to several cell lines that do not
express detectable mRNA for TACI and BCMA and prote-
oglycans were identified as APRIL-specific binding part-
ners. This binding is mediated by heparan sulfate (HS)
side chains and can be inhibited by heparin[26,27]. Bind-
ing of APRIL to proteoglycans or BCMA/TACI involves dif-
ferent regions in APRIL. APRIL binds HS proteoglycans via
the lysine-rich region in the N-terminal part, leaving the
TNF-like region available to interact with others receptors.
Blockade of APRIL/BAFF using human BCMA-Ig in nude
mice inhibited the growth of a subcutaneously injected
human lung carcinoma cell line (A549) and a human
colon carcinoma cell line (HT29)[28]. These cell lines
express APRIL, but not BAFF, TACI, BCMA or BAFF-R sug-
gesting that HS proteoglycans could mediate the growth
response to APRIL. However, BCMA-Fc leaves the APRIL
binding HSPG domain intact. This blockade may suggest
that the TNF-receptor binding domain is also necessary
for activity, and that an additional APRIL-specific receptor
might exist. B-cell lymphoma cells can bind large amount
of APRIL secreted by neutrophils via proteoglycan binding
and the high expression of APRIL in tumor lesion corre-
lates with B-cell lymphoma aggressiveness[16]. More
recently, Bischof et al demonstrated that TACI binds also
HS proteoglycans like syndecan-1, syndecan-2 and synde-
can-4 [29].
These data demonstrate that BAFF/APRIL are potent
growth factors in B cell malignancies. Furthermore, APRIL
could be implicated in tumor emergence and/or progres-
sion due to its ability to bind HS proteoglycans [26-28].
Therefore, we looked for the expression of BAFF, APRIL
and of their receptors – BAFF-R, BCMA, and TACI – in var-
ious cancers, compared to their normal tissue or cell coun-
terparts and in association with disease staging.
Methods
Databases
We used Oncomine Cancer Microarray database http://
www.oncomine.org[30] and Amazonia database http://
amazonia.montp.inserm.fr/[31] to study gene expression
of BAFF, APRIL, BCMA, TACI, BAFF-R and HS proteogly-
cans genes in 40 human tumor types and their normal tis-
sue counterparts as indicated in Table 1 (Additional file
1). Only gene expression data obtained from a single
study using the same methodology were compared. All
data were log transformed, median centred per array, and
the standard deviation was normalized to one per
array[32].
Statistical analysis
Statistical comparisons were done with Mann-Whitney or
Student t-tests.
Results and Discussion
BAFF is overexpressed in solid tumors
40 tumor types were investigated, including 36 solid
tumors and 4 hematological tumors (Additional file 1:
Table 1). BAFF gene is overexpressed in 1/4 hematological
tumors and in 5/36 solid tumors. BAFF is overexpressed in
Hodgkin lymhoma compared to normal B cells (P = 4.9E-
11), in Burkitt lymphoma compared to normal B cells (P
= 5.4E-5), in diffuse large B cell lymphoma compared to
normal B cells (P = .01) and in follicular lymphoma com-
pared to normal B cells (P = 2E-6)[33]. Four independent
studies have shown BAFF overexpression in glioblastoma
compared to normal brain (P = 5.4E-13, P = 8E-6, P =
5.3E-5 and P = 0.008) [34-37] (Figure 1). Following stim-
ulation with inflammatory cytokines, astrocytes in vitro
produce high amounts of BAFF. BAFF  is expressed in
astrocytes in the normal human central nervous system
and is strongly upregulated in activated astrocytes in the
demyelinated lesions of multiple sclerosis[38]. BAFF
secretion could be relevant in sustaining intrathecal B cell
responses in autoimmune and infectious diseases of the
central nervous system. Accordingly, BAFF expression is
readily induced in the central nervous system by neuro-
trophic viruses and correlates with the recruitment of anti-
body-secreting cells[39]. The overexpression of BAFF in
brain tumors could be linked to the accumulation of
tumor cells or to inflammatory signals. Regarding other
cancers, BAFF  was found significantly overexpressed in
breast carcinoma compared to normal breast (Richardson
et al[40]; P  = 2.4E-7), in esophageal adenocarcinoma
compared to normal esophagus (Hao et al[41]; P = 3.7E-
4), in clear cell renal cell carcinoma compared to normal
kidney (Lenburg et al[42]; P = 2.1E-5) and in adult male
germ cell tumor compared to normal testis (Korkola et
al[43]; P = 8.3E-18).
APRIL is overexpressed in solid and hematological 
malignancies
APRIL gene was overexpressed in 1/4 hematological and
in 6/36 solid tumors in tumors (Additional file 1: Table
1).  APRIL  was overexpressed in invasive bladder carci-
noma compared to superficial bladder carcinoma in two
independent studies (P = 3.3E-6 and P = 0.003)[44,45], in
esophageal adenocarcinoma compared to normalBMC Cancer 2009, 9:83 http://www.biomedcentral.com/1471-2407/9/83
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BAFF expression in various cancers Figure 1
BAFF expression in various cancers. BAFF gene expression in normal brain, glioblastoma multiforme [34-37], normal 
breast, breast carcinoma[40], normal esophagus, esophageal adenocarcinoma[41], normal kidney, renal carcinoma[42], normal 
testis, adult male germ cell tumor[43], Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma and follicular lym-
phoma[33]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously 
described[32]. In brackets, are indicated the number of normal or tumor samples.BMC Cancer 2009, 9:83 http://www.biomedcentral.com/1471-2407/9/83
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esophagus in two independent studies (P = 3.7E-4 and P
= 5.5E-4)[41,46], in glioblastoma compared to normal
brain in two independent studies (P = 3.5E-4 and P =
0.006)[34,36], in head and neck carcinoma compared to
normal oral mucosa in two independent studies (P  =
9.2E-10 and P = 0.009)[47,48], in diffuse large B cell lym-
phoma compared to normal lymph nodes (P  = 7.6E-
6)[49,50], in pancreatic adenocarcinoma compared to
normal pancreas (Iocobuzio-Donahue et al[51]; P  =
0.002) and in adult male germ cell tumor compared to
normal testis (Korkola et al[43]; P = 1.6E-11) (Figure 2).
Recently, Schwaller et al[16] demonstrated that high
APRIL expression in tumor lesions correlates with B-cell
lymphoma aggressiveness. We found here that BAFF or
APRIL  expression could be also associated with tumor
aggressiveness in other cancers (Figure 3). APRIL is signif-
icantly overexpressed in glioma grade 4 compared to gli-
oma grade 3 (P  = 3.1E-12) and in patients presenting
glioma, dead at 3 years compared to patients alive at 3
years (P = 1.8E-4)[52] (Additional file 2). In bladder car-
cinoma, APRIL is overexpressed in patients dead at 3 years
compared to patients alive at 3 years (P = .005)[53]. High
tumor cell mass in breast cancer was also characterized by
increased APRIL expression in two independent studies (P
= .003 and P = .004)[54,55]. Stages II, III and IV cervical
carcinoma showed an overexpression of APRIL compared
to stage I (P = 0.003)[56] (Figure 3). On the contrary,
BAFF overexpression was not associated with prognosis or
tumor aggressiveness using online cancer gene expression
analysis[32]. APRIL protein was detected in several
human solid tumors[57] and normal epithelial cells[11].
Interestingly, APRIL protein expression was reported in
larynx and oral cavity carcinoma, esophagus carcinoma,
bladder carcinoma, breast cancer, pancreatic tumors,
ovarian carcinoma, seminoma adenocarcinoma, glioblas-
toma multiforme and oligodendroglioma correlating
with the results of our analysis[57,58]. In addition, neu-
trophils, present in the stroma of solid tumors, are major
producers of APRIL [57] suggesting that APRIL overexpres-
sion may be due to infiltrating cells. Furthermore, APRIL
that is produced in tumors is retained and accumulates in
the tumor stroma though HSPG binding[57]. Neverthe-
less, an upregulation of APRIL protein (detected by in situ
immunostaining) was shown to not alter disease-free and
overall survivals of bladder, ovarian and head and neck
carcinoma patients in retrospective studies[58]. We have
identified here a significant overexpression of APRIL in
patients with glioma or bladder carcinomas who were
dead at 3 years compared to patients alive at 3 years. An
explanation could be that a part of APRIL protein is
quickly secreted and no more detectable by immunostain-
ing. APRIL protein could also be used by tumor cells as a
growth factor or released in the blood circulation.
TACI is overexpressed in hematological cancers
We have previously reported the relevance of Affymetrix
microarrays to quantify BCMA and TACI expressions in
MM since microarray data were validated by real time RT-
PCR and flow cytometry[20,21,59]. No differences in
BCMA  or  BAFF-R  expression between tumor cells and
their normal counterparts could be found in the 40 cancer
types available from Oncomine database. By contrast, a
significant TACI overexpression was found in smoldering
myeloma compared to normal plasma cells (Zhan et
al[60]; P = 0.0009) and in thyroid carcinomas compared
to normal thyroid (Huang et al[61]; P = 0.005) (Figure 4).
Interestingly, we found that TACI expression is associated
with a poor prognosis in Burkitt lymphoma. TACI is sig-
nificantly overexpressed in patients presenting Burkitt
lymphoma who were dead at five years compared to
patients alive at five years (Dave et al[62]; P = 0.004) (Fig-
ure 4). Recently, it was described that APRIL-TACI interac-
tions mediate non-Hodgkin lymphoma B-cell
proliferation through Akt, regulating cyclin D1 and P21
expression[63]. These data suggest that TACI is the main
receptor for BAFF/APRIL in lymphoma cells and is associ-
ated with a bad prognosis. TACI therefore represents a
potential lymphoma therapeutic target.
Correlations between APRIL and heparan sulfate chain 
proteoglycans overexpression in tumor cells
Receptors for BAFF and APRIL are expressed exclusively by
lymphoid cells. APRIL can bind and promote tumor-cell
proliferation of several cell lines that do not express
detectable mRNA for TACI and BCMA[9,64,65]. Ingold et
al  and Hendriks at al identified proteoglycans as the
APRIL-non specific binding partners. This binding is
mediated by HS side chains and can be inhibited by
heparin[26,27]. Only APRIL expression was associated
with a bad prognosis in several cancers. APRIL could sus-
tain the survival of malignant cells directly through HS
proteoglycans that can deliver signals through their intra-
cellular tails upon binding to ligands[66,67].
Eleven HS proteoglycans has been identified so far – syn-
decan 1–4, glypican 1–6, CD44 isoforms containing the
alternatively spliced exon v3 – and their gene expression
can be evaluated by microarrays[68] (see Additional file
3). Interestingly, at least one HS proteoglycan gene was
significantly overexpressed in cancers presenting an over-
expression of APRIL compared to their normal counter-
parts (see Additional file 1). A similar observation was
made for cancers showing an association between APRIL
expression and the evolution of the disease (see Addi-
tional file 1).
HS proteoglycans regulate growth factor signaling,
cytoskeleton organization, cell adhesion and migra-
tion[69]. HS proteoglycans are implicated in solid tumorBMC Cancer 2009, 9:83 http://www.biomedcentral.com/1471-2407/9/83
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APRIL expression in various cancers Figure 2
APRIL expression in various cancers. APRIL gene expression in normal bladder, bladder carcinoma[44,45], normal 
esophagus, esophageal adenocarcinoma[41,46], normal brain, glioblastoma multiform[34,36], normal oral mucosa, head and 
neck carcinoma[47,48], normal B cell, lymphoma[49,50], normal pancreas, pancreatic adenocarcinoma[51], normal testis and 
adult male germ cell tumor[43]. Data sets in a single panel were from the same study. GEP data are log transformed and nor-
malized as previously described[32]. In brackets, are indicated the number of normal or tumor samples.BMC Cancer 2009, 9:83 http://www.biomedcentral.com/1471-2407/9/83
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development[70,71]. Syndecan-1 is absolutely required
for the development of mammary tumors driven by the
transgenic expression of the proto-oncogene Wnt-1 in
mice[72]. The important role of HS proteoglycans is
attributed in part to its highly negative electric potential,
making it able to bind numerous proteins and to function
as a coreceptor. However as APRIL activates cells that do
not express TACI or BCMA, a direct signaling by the HS
proteoglycans core protein is possible as already shown
[66]. It may explain the overexpression of APRIL in asso-
ciation with disease aggressiveness in solid tumors which
do not express BCMA or TACI. Nevertheless, additional
studies are required to understand the exact role of APRIL
in solid tumors, the existence of a signaling linked to the
interaction of APRIL with HS proteoglycans and the pos-
sible existence of a receptor specific to APRIL not yet iden-
tified.
Conclusion
The analysis reported here demonstrates that APRIL
mRNA is overexpressed in at least 8 cancers compared to
their normal counterparts, and within a given tumor cate-
gory, is associated with a bad prognosis. These observa-
tions emphasize the interest using BAFF/APRIL inhibitors
in the treatment of patients with cancers. We recently
completed a phase I-II clinical trial of Atacicept TACI-Fc
inhibitor showing the feasibility and safety of this target-
ing in multiple myeloma (submitted data). Heparin could
be also useful in blocking APRIL binding to surface HS
proteoglycan. Of note, we found here always one HS pro-
teoglycan gene overexpressed in tumors that also highly
expressed APRIL. A recent study reported that a brief
course of subcutaneous low molecular weight heparin
favorably influences the survival in patients with
advanced malignancy and deserves additional clinical
evaluation[73]. Thus, the targeting of APRIL or its interac-
tion with HS proteoglycans may be promising in a large
number of cancers.
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